Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

CVS Caremark adds Access' MuGard to pharmacy benefit network

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network.

15 Jul 2011

NeoStem to acquire Amorcyte

NeoStem, Inc., an international biopharmaceutical company, announced the signing of a definitive merger agreement whereby NeoStem will acquire Amorcyte, Inc., a development stage cell therapy company focusing on novel treatments for cardiovascular disease.

15 Jul 2011

Verastem raises $32 million to develop targeted cancer stem cell therapies

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced today that it has raised $32 million through a Series B financing. Proceeds from the financing will support ongoing research and development and will progress drug candidates into clinical development. The first candidate is projected to enter the clinic in 2012.

14 Jul 2011

Vitrolife second quarter sales increase 19% to SEK 88 million

Vitrolife: Second quarter in brief. Sales growth increased by 31 percent in local currency in the second quarter. Sales amounted to SEK 88 (73) million, corresponding to an increase by 19 percent in SEK.

14 Jul 2011

Study overturns long-accepted theories about fundamental aspect of tissue regeneration

Scientists have been wrong for 250 years about a fundamental aspect of tissue regeneration, according to a University of Dayton biologist who says his recent discovery is good news for humans.

14 Jul 2011

Researchers capitalize on 'memories' of adult-derived stem cells for treatment of diabetes

Stem cells from early embryos can be coaxed into becoming a diverse array of specialized cells to revive and repair different areas of the body. Therapies based on these stem cells have long been contemplated for the treatment of diabetes, but have been held back by medical and ethical drawbacks.

14 Jul 2011

UCI study sheds light on how transplantation alleviates side effects of radiotherapy

Human neural stem cells are capable of helping people regain learning and memory abilities lost due to radiation treatment for brain tumors, a UC Irvine study suggests.

14 Jul 2011

Patients with brain cancer may benefit from stem cell therapy

Stem cell therapy may restore cognition in patients with brain cancer who experience functional learning and memory loss often associated with radiation treatment, according to a laboratory study published in Cancer Research, a journal of the American Association for Cancer Research.

14 Jul 2011

Chimerix initiates CMX001 Phase 2 study for prevention of adenovirus disease following HSCT

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation [HSCT]).

14 Jul 2011

Celprogen develops neuronal stem cells to treat Alzheimer's

Celprogen has developed neuronal stem cells that can be differentiated into neurons as an alternative for Cell based therapy for neurological diseases including Alzheimer's patients.

13 Jul 2011

Blood cancer drug trial results questioned by FDA

U.S. drug reviewers might limit the use of a Seattle Genetics Inc’s experimental blood cancer drug due to the narrow scope of its clinical trials. According to papers released Tuesday by the Food and Drug Administration (FDA), it requests an advisory panel to consider the drug, under the proposed trade name Adcetris known chemically as brentuximab vedotin, for use in previously treated patients with Hodgkin's lymphoma and anaplastic large cell lymphoma (ALCL).

13 Jul 2011

New animal model for studying development of testicular germ cell tumors

A team of researchers from Spain and Switzerland have developed a new model for studying the development of testicular germ cell tumors by transplanting embryonic stem cells into the seminiferous tubules in mouse models, resulting in the development of testicular germ cell tumors (TGCT) that mimic the early stages of TGCT development.

12 Jul 2011

Ipsen, Salk Institute renew Life Sciences Program

Ipsen and The Salk Institute for Biological Studies announced today that they are renewing the Ipsen Life Sciences Program at The Salk Institute.

12 Jul 2011

genOway acquires worldwide exclusive license for RMCE technology from bluebird bio for genetically modified rodents

genOway and bluebird bio report today genOway acquisition of an exclusive worldwide license for the RMCE technology (developed at the Massachusetts Institute of Technology) in the field of genetically modified rodents.

12 Jul 2011

Hutchinson Center receives $20M NIH grant to eradicate HIV infection

Whether a stem cell transplant using an HIV-infected person's own genetically modified immune cells can become a cure for the disease is the focus of a new $20 million, five-year research grant award announced today by the National Institutes of Health to Fred Hutchinson Cancer Research Center.

12 Jul 2011

Cancer Cell publishes Epizyme and collaborators' breakthrough research on MLL

Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer and rare disease patients, and its collaborators announced the publication in Cancer Cell of breakthrough research in the treatment of MLL-rearranged leukemia (MLL), a genetically-defined subset of acute lymphoblastic leukemia and acute myelogenous leukemia.

12 Jul 2011

Ion Torrent ships three next-generation sequencers

Ion Torrent, a unit of Life Technologies Corporation, today announced that it is shipping its new 100 Mb Ion 316 chip, which has tenfold more throughput than the original Ion 314 chip, and that its 1 Gb Ion 318 chip will be available in the fourth quarter.

11 Jul 2011

CCBC repurchases an aggregate of 2,052,607 ordinary shares

China Cord Blood Corporation, the first and largest cord blood banking operator in China, today announced that the Company repurchased an aggregate of 2,052,607 ordinary shares.

11 Jul 2011

Scientists convert brain cells into cardiomyocytes

For the past decade, researchers have tried to reprogram the identity of all kinds of cell types. Heart cells are one of the most sought-after cells in regenerative medicine because researchers anticipate that they may help to repair injured hearts by replacing lost tissue.

11 Jul 2011

Life Technologies introduces new India Distribution Center

Life Technologies Corporation announced today that it has launched a regional distribution hub in India to address strong customer demand in the South Asia region.

11 Jul 2011